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Abstract
Background: Ocular albinism type 1 (OA1) is an X-linked ocular disorder characterized by a
severe reduction in visual acuity, nystagmus, hypopigmentation of the retinal pigmented epithelium,
foveal hypoplasia, macromelanosomes in pigmented skin and eye cells, and misrouting of the optical
tracts. This disease is primarily caused by mutations in the OA1 gene.
Methods: The ophthalmologic phenotype of the patients and their family members was
characterized. We screened for mutations in the OA1 gene by direct sequencing of the nine PCR-
amplified exons, and for genomic deletions by PCR-amplification of large DNA fragments.
Results: We sequenced the nine exons of the OA1 gene in 72 individuals and found ten different
mutations in seven unrelated families and three sporadic cases. The ten mutations include an amino
acid substitution and a premature stop codon previously reported by our team, and eight
previously unidentified mutations: three amino acid substitutions, a duplication, a deletion, an
insertion and two splice-site mutations. The use of a novel Taq polymerase enabled us to amplify
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Furthermore, we were able to confirm that there was no deletion in twenty one patients where
no mutation had been found.
Conclusion: The identified mutations affect highly conserved amino acids, cause frameshifts or
alternative splicing, thus affecting folding of the OA1 G protein coupled receptor, interactions of
OA1 with its G protein and/or binding with its ligand.
Background
Ocular albinism type 1 (Nettleship-Falls type, OMIM
+300500) is the most common form of ocular albinism.
The disease is transmitted as an X-linked disorder, in
which affected males show all the ocular signs of albi-
nism: severely impaired visual activity, nystagmus, photo-
phobia, iris transillumination, hypopigmentation of
retinal pigmented epithelium, foveal hypoplasia and mis-
routing of optic tracts. Most female carriers (90%) show
minor fundal signs, suggesting a potential carrier status.
Most of the affected patient'mothers present a typical
mosaic pattern of depigmentation assumed to represent
the effect of random X-inactivation (Lyonization) of the
OA1 gene. However, in some mothers the depigmenta-
tion pattern looks very subtle and may correspond to nor-
mal fundoscopic aspects.
The OA1 gene (GPR143, [GenBank NM_000273]) is
expressed in skin and retinal pigmented epithelial cells. In
these cells, the melanosomes are larger than normal
melanosomes [1,2]. The OA1 protein is a G protein-cou-
pled receptor (GPCR) that is embedded in the melano-
some membrane [3], with the N-terminus of the protein
in the melanosome lumen and the C-terminus in the
cytosol. OA1 is the only known intracellular GPCR and its
signaling pathway is involved in regulating melanosome
biogenesis and growth [4,5]. The OA1 ligand, which is
presumably present inside the melanosome, remains
unknown [6].
Ocular albinism is primarily caused by mutations in the
OA1 gene [7]. The OA1 gene spans about 40 kb of
genomic DNA in chromosome Xp22.3 and contains nine
exons [8]. Many different mutations have been reported,
some of which cause abnormal folding of the protein.
Other mutations affect the receptor interaction with its G
protein, thus altering the signaling pathways, or with its
ligand [9]. So far, 44 mutations and 18 deletions have
been discovered [10,11]. However, no mutations have
been reported in the C-terminal end of the protein.
We screened 72 individuals, representing 37 probands,
and identified mutations in seven unrelated families and
three patients with sporadic disease. We found eight pre-
viously unidentified mutations: three missense muta-
tions, a duplication, a deletion, an insertion and two
splice-site mutations. We also found two mutations previ-
ously reported by our team: one missense and one non-
sense mutation [12]. These ten mutations were named
using the international nomenclature [13]. Nucleotide
numbering used the A of the ATG start codon as nucle-
otide +1. Moreover, we detected six probable deletions
which remain to be characterized.
Methods
Patients
The study population consisted of 72 individuals, repre-
senting 37 probands. 39 of these individuals were affected
by ocular albinism, 27 were carriers and 6 were unaffected
individuals. We included in this study 100 ethnically
matched control individuals not affected by any form of
albinism. We analyzed the exon sequences and the
intron/exon boundaries of the OA1 gene in all 72 sub-
jects. Whenever possible, affected males and their families
underwent clinical ophthalmologic examination, includ-
ing visual acuity testing, fundus examination and mul-
tichannel visual evoked potential analysis to confirm X-
linked ocular albinism. Blood samples were collected
from patients after signed informed consent by the adults
or by both parents for each child involved in the study. We
strictly obeyed the rules of bioethical laws of the European
Union and France, as well as the guidelines of the Helsinki
Declaration.
DNA amplification and sequencing
We extracted genomic DNA from the lymphocytes of all
subjects, and amplified all nine exons from all the sam-
ples by PCR using intronic oligonucleotide primers. We
generated two overlapping PCR fragments (A for upper
fragment and B for lower fragment) for exons 1, 8 and 9,
because of their length. The primer sequences were:
1AF-GAGCCTGGCTCTACTGCAGGCGCTG, 1AR-CCTTC-
CACGCGCTCTGGCT, 1BF-AGCCACGCAGCTCGTGCT-
GAGCTTCCAGCC, 1BR-
CCGCGGGTTGGAATCTGATCAGCGCCTGGG, 2F-
TGATTAGGATCAGATACAAAG, 2R-CCTACTTATGCTC-
CTCAAAG, 3F-TTCTTGTACCTGTTTCCAGAC, 3R-CAA-
GATAAGAGATGGCACTGA, 4F-
AGTTCCAGGCAGGCCTCTGT, 4R-TCTTGCAGGGAATA-
CATGAGC, 5F-CATCCTCTTATCTTGACTTCC, 5R-ACT-
AGGGAAGCTCTCTGGG, 6F-Page 2 of 8
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GGCTATGGAA, 7F-CATGTTCTCTTTACCTGCTGC, 7R-
CTTCAGAGACAAGGTCTCACT, 8AF-CTGCACTGACT-
GCCATGTGTC, 8AR-GAATCACTGACCACCTCGGCT, 
8BF-CAGTCTCCCAGGAAGGAGATC, 8BR-GAAGTCTAC-
CTGCTGTGGCAG, 9AF-AGCTGATGACAAACCTGCTAG, 
9AR-CTTTAGGATAGGAGAAAGGG, 9BF-CCCATATTC-
CTCAGACTCAAC, 9BR-TGGATTCTGTCTTAACACTTC.
The conditions of amplification of each fragment are
available upon request. The DNA fragments were then
purified on NucleoFast plates (Macherey-Nagel) and the
sense and antisense strands were sequenced on an ABI
777 Machine (Applied Biosystems) by the INSERM core
automated sequencing facility of Hôpital Cochin, Paris.
Splice site mutations
We analyzed sequences that could contain nucleotide
changes that could affect the splicing of the OA1 gene
using NNSPLICE 0.9 software [14] to search for potential
abnormal new splice sites generated by mutations.
Sequence aligments
The OA1 protein was then aligned with its orthologs and
other GPCRs using BioEdit software [15] and other online
software, such as Pfam [16], to determine the conserva-
tion of modified amino acids between species and among
GPCRs.
Deletions
The OA1 gene was screened for deletions by PCR on
genomic DNA, using TaKaRa LA Taq enzyme (Cambrex).
We divided OA1 in three fragments, 15 kb each. The
primer sequences used for the long-rang amplifications
were:
OA1-1-F: CCCAAATAGGAAAGATCTAGTCCACGAGGC,
OA1-1-R: ACTTACTCCTCTTACAGCCTCATCCCAGGA,
OA1-2-F: GCAGGCTTGAGCTCAGGAGTTTGAAGTTAC,
OA1-2-R: GCCTGGTAGAGTTTGGGGCAGTCATAAGTA,
OA1-3-F: CCACCAGCTGGAACTGCTGTTAGTCTGTAG,
OA1-3-R: CTGTCTTCTCTGCCCCCTAGTGTGTGTTAG.
The conditions of amplification of each fragment are
available upon request.
We also looked carefully at the PCR electrophoresis gels as
well as the chromatograms, in order to detect which exons
could be deleted.
Results
After ophthalmological examination, we found that the
visual acuity of all affected individuals was severely
impaired compared to age-, sex- and refractive error-
matched normal patients. Female carriers had a mosaic
depigmentation pattern of their fundus which could be
related to X chromosome inactivation (Lyonization).
Control patients had no abnormality of their skin and eye
pigmentation.
The molecular genetics results are summarized in Table 1
and shown in Figures 1, 2, 3, 4, 5. We found two previ-
ously described mutations [12]. The first nucleotidic
change, c.401T>C (p.L134P amino acid change, Figure
1A, 1B, 1C), located in exon 3, was found in two related
families. In one family, I2 and her daughter II3 carry the
mutation in the heterozygous state, whereas in the other
family, II2, who turned out to be the sister of II3, is heter-
ozygous whereas her son, III1, is hemizygous. In a third
branch previously reported by our team [12], II4, found to
be the other sister of II3, is heterozygous whereas her son,
III3, is hemizygous. The second already found nucleotidic
mutation, the R285X change (c.853A>T, Figure 1D),
located in exon 7, was found in another patient which was
apparently a sporadic case.
Table 1: Mutations of OA1. The amino acid changes were deduced from the genomic sequence.
Patient Nucleotide change Amino acid change Exon Protein domain Reference
A (familial case) 401T->C L134P 3 TMIII [12]
B (Canadian sporadic case) 853A->T R285X 7 l3 [12]
C (French familial case) 241G->T G81V 1 TMII Previously unidentified mutation
D (Canadian sporadic case) 348C->G C116W 2 l1 Previously unidentified mutation
E (French sporadic case) 497C->A T166N 4 TMIV Previously unidentified mutation
F (French sporadic case) 163_170dupGCGGGCCC G58fsX29 (Frameshift) 1 i1 Previously unidentified mutation
G (French sporadic case) 504_505delCT L168fsX58 (Frameshift) 4 TMIV Previously unidentified mutation
H (Canadian sporadic case) 601_602insT P201fsX25 (Frameshift) 5 TMV Previously unidentified mutation
I (Canadian sporadic case) 547+2T->A Splice site mutation 4 TMIV Previously unidentified mutation
J (Canadian sporadic case) 886-2A->T Splice site mutation 8 l3 Previously unidentified mutationPage 3 of 8
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point mutationsFigure 1
point mutations. 1A: chromatogram of the 401T>C mutation (L134P), from a carrier, obtained with Chromas 2.3. The nucle-
otide change resulting from the mutation is shown on the chromatogram. 1B: pedigree of the whole family with its three 
branches: solid squares are affected people, dotted circles are molecularly proven carriers and hollow squares and circles are 
unaffected people. Here, I2 and II 1, 2 and 3 are carriers, III1 and 3 are affected. The mutation was previously described in II3 
and III3 [12]. 1C: sequence alignment of OA1 between different species: MOUSE: Mus musculus, HUMAN: Homo sapiens, 
XENTR: Xenopus tropicalis, XENLA: Xenopus laevis, BRARE: Danio rerio, ANOGA: Anopheles gambiae. The arrows in the 
alignment show the amino acid affected by the mutation. 1D: chromatogram of the 853A->T mutation (R285X), from an 
affected individual. 1E: chromatogram of the 241G>T mutation (G81V), from an affected individual. 1F: pedigree of the family 
affected by G81V. 1G: sequence alignment around G81. 1H: chromatogram of the 348C>G mutation (C116W), from a carrier. 
1I: pedigree of the family affected by C116W. 1J: sequence alignment around C116. 1K: chromatogram of the 497C>A muta-
tion (T166N), from an affected individual. 1L: pedigree of the family affected by T166N. 1M: sequence alignment around T166.
BMC Medical Genetics 2006, 7:41 http://www.biomedcentral.com/1471-2350/7/41We also found eight previously unidentified mutations in
six other unrelated families and two other isolated cases.
We observed a c.241G>T mutation (p.G81V, Figure 1E,
1F, 1G) located in exon 1 in two affected brothers (II1 and
II2) as well as in their uncle (I3) in the hemizygous state
and in their mother (I2) in the heterozygous state.
We detected a c.348C>G mutation (p.C116W, Figure 1H,
1I, 1J) located in exon 2 in a male patient (II2) in the
hemizygous state and in his sister (II1) and mother (I2) in
the heterozygous state.
We found a c.497C>A mutation (p.T166N, Figure 1K, 1L,
1M) located in exon 4 in a male patient (II1) in the
hemizygous state and in his mother (I2) in the hetero-
zygous state.
We found an 8-base pair duplication
(c.163_170dupGCGGGCCC, Figure 2) located in exon 1
in an affected male (II1) in the hemizygous state, and in
his mother (I2) in the heterozygous state.
We also found a 2-base pair deletion (c.504_505delCT,
p.L168fsX58, Figure 3) located in exon 4 in an affected
male (II1) in the hemizygous state, and his mother (I2) in
the heterozygous state, and a 1-base pair insertion
(c.601_602insT, p.P201fsX25, Figure 4) located in exon 5
in a sporadic case.
We found two splice site mutations. One of these is
located just after exon 4 (c.547+2T>A, Figure 5A, 5B), in
the 5' consensus donor region for the splicing of intron 4–
5. This mutation was found in the hemizygous state in an
affected patient (III1), and in the heterozygous state in his
mother (II2) and his maternal grandmother (I2).
The other splice site mutation (c.886-2A>T, Figure 5C),
located in the 3' consensus acceptor region for the splicing
of intron 7–8, was found in an isolated case.
The OA1 gene from all the control individuals included in
this study was sequenced, and we found none of the
mutations that we detected in the OA1 gene sequences.
The 27 patients who apparently did not carry any OA1
mutation in our initial mutational screening were
screened for large genomic deletions in the OA1 gene. The
deletionFigure 3
deletion. 3A: chromatogram of the 504_505del(CT)muta-
tion, from an affected individual. 3B: pedigree.
duplicationFigure 2
duplication. 2A: chromatogram of the 163_170dup(GCGGGCCC) mutation, from an affected individual. 2B: pedigree.Page 5 of 8
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BMC Medical Genetics 2006, 7:41 http://www.biomedcentral.com/1471-2350/7/41use of the TaKaRa Taq enzyme combined with the analysis
of the gels and chromatograms led us to conclude that
twenty-one patients did not to carry any deletion. We are
working on three familial cases and three isolated patients
who present abnormal amplification of the gene (data not
shown) but their genetic alterations are not characterized
yet.
Discussion
We studied 39 individuals with ocular albinism and
members of their families. We found mutations in 12
individuals out of 39 (31%) with a clinical diagnosis of
ocular albinism. We found two previously reported muta-
tions and eight novel sequence changes in the OA1 gene.
Among the previously reported mutations, the L134P
change was found in what seemed to be three unrelated
French families. These families were initially examined in
two different countries, by three different ophthalmolo-
gists and three different medical geneticists. Details about
the extended family were either overlooked or not known.
The same nucleotide mutation (401T>C) was not found
in 100 ethnically matched control patients. From a metic-
ulous study by interview of the patients' pedigree, it was
found that these families are three branches of the same
family (Figure 1B). The unmarried lone daughter (II3) of
one family and the mothers of the other two families (II2
and II4) are in fact three sisters who had not readily dis-
closed their biological familial links. Sequence alignment
analysis showed that L134 is conserved among all tetra-
pod OA1 proteins. This result suggests that this amino
acid may play a key role in OA1 protein function. There-
fore a mutation of this leucine residue, located in the third
transmembrane domain, may result in a non-functional
protein and explains the severe visual phenotype observed
in the affected patients.
The mutation R285X resulted in the OA1 protein being
truncated in its third luminal loop.
The G81V mutation affects a glycine residue conserved
among the vertebrate orthologs of OA1. This valine resi-
due, located in the second transmembrane domain, is
larger than the glycine residue and may prevent the pro-
tein from folding correctly.
The C116W mutation affects a cysteine residue that is highly
conserved between all species and among all GPCRs. This
cysteine is thought to form a disulfide bond with C184,
allowing the correct folding of the receptor. The mutation
modifies the protein in the very end of the first luminal
loop. Thus, the protein cannot fold properly and is therefore
splice site mutationsFigure 5
splice site mutations. 5A: chromatogram of the 547+2T->A 
mutation, from an affected individual. 5B: pedigree of the 
family affected by the 547+2T->A mutation. 5C: chromato-
gram of the 886-2A->T mutation, from an affected individual.
insertionFigure 4
insertion. 4A: chromatogram of the 601_602ins(T) mutation, 
from an affected individual.Page 6 of 8
(page number not for citation purposes)
BMC Medical Genetics 2006, 7:41 http://www.biomedcentral.com/1471-2350/7/41completely non-functional [17]. Two other mutations have
been reported to affect this amino acid: C116S and C116R
[9,18].
Alignments of all the vertebrate OA1 proteins show that a
hydrophobic amino acid is found in most vertebrate OA1
proteins at the position corresponding to the human OA1
amino acid residue 166, which is normally a threonine
(figure 1M). Although threonine and asparagine are both
polar amino acids, threonine is much less hydrophilic
than asparagine which is the mutated amino acid. Moreo-
ver, substituting the threonine at codon 166 with an
asparagine substantially changes the residue side chain at
a critical position of the fourth transmembrane domain,
in the OA1 protein. Therefore, this amino acid substitu-
tion very likely causes structural and functional alterations
to OA1 and is thus very likely to be highly pathogenic.
The c.163_170dupGCGGGCCC duplication is located in
the region encoding the first intracellular loop and
induces a frameshift and a premature stop codon
(p.G58fsX29). This truncates the protein in its second
transmembrane domain, completely preventing any func-
tion of the OA1 protein.
Both c.504_505delCT and c.601_602insT mutations
induce a frameshift and a premature stop codon, truncat-
ing the protein in its third intracellular loop.
We used NNSPLICE in order to analyze the mutated
mRNAs resulting from the splice site mutations, and we
found that they had displaced splice sites, with neighbor-
ing cryptic splice sites being used instead of the missing
normal splice site. This resulted in short erratic sequences
ending with a stop codon after the normal sequence.
Mechanistically, this observation is somewhat reminis-
cent of that previously reported by our lab in a case of
pyruvate dehydrogenase deficiency [19]. Thus, if the
abnormal mRNA are actually translated and escape degra-
dation, the encoded proteins are truncated and non-func-
tional.
Recent findings have shown that new splice sites can
appear within introns, leading to aberrant mRNA [19,20].
These splice sites cannot be found at the genomic DNA
level by using screening techniques limited to exons and
canonical splice sites at the exon boundaries [19]. We
observed 21 patients who had apparently no OA1 gene
mutations or deletions despite presenting an apparently
X-linked form of ocular albinism. These patients may
have this type of intron mutation or may have mutations
that alter the regulatory regions of the gene, such as the
promoter region, silencers or enhancers.
Normally, with the techniques currently used for the
molecular genetics diagnosis of X-linked ocular albinism,
one third of affected individuals is not found to carry such
mutations [10]. Other patients have a completely or par-
tially deleted gene.
Apparently sporadic cases may be due to several reasons.
In some instances, we could simply not be able to get all
the DNA samples of the families. Sometimes, de novo ger-
minal alterations could have arisen, the mechanisms of
which are diverse, including DNA lesions and repair or
recombinations during meiosis [21]. The latter mecha-
nism looks more plausible, as there may be many
repeated sequences within introns or around the gene,
leading to misalignments of X chromosomes during mei-
osis and unequal crossing-over(s). This may explain the
high deletion rate in OA1 gene. Germinal mosaicism may
also be a cause of sporadic deletion in OA1.
Another possibility is that some of these patients may
have been considered erroneously as affected by X-linked
ocular albinism while they are in fact affected by very mild
forms of oculocutaneous albinism. The limited size of the
pedigrees analyzed in this study prevents us from stating
with certainty the mode of inheritance of all the clinically
diagnosed ocular albinisms included in our cohort. We
cannot rule out that ocular albinism may constitute a het-
erogenous genetic ensemble despite being apparently
clinically homogenous. However, in light of all the studies
published so far, this hypothesis is very unlikely and all
clinical forms of ocular albinism appear with a very high
degree of probability linked to genetic alterations of the
OA1 gene, despite the variability of symptoms observed
in different patients [22].
Studying the size and the sequences of the mRNA from
genes encoding proteins involved in melanogenesis is
hindered by the extreme difficulty in their amplification
by RT-PCR of total RNA extracted from lymphoblastoid or
fibroblast cell lines from affected patients. The illegitimate
transcription of such cell lines to obtain cDNA corre-
sponding to the transcripts encoding melanogenic pro-
teins has never been shown to be particularly efficient.
Indeed, these genes either are not transcribed or are only
weakly transcribed in these cell lines. Therefore, we would
need to obtain skin biopsies from affected patients, purify
melanocytes from these samples, culture them and then
extract total RNA from these cultures before carrying out
RT-PCR.
Our mutational screening would certainly benefit from
quantitative genomic PCR [23] in order to increase the
probability of detecting other OA1 mutations that may
have gone unnoticed by the sequencing procedure used
for small, amplified exon fragments studied in this report.Page 7 of 8
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Our results highlight the role of key amino-acids in both
OA1 structure and function, as well as the need for
detailed study of the molecular mechanisms of the splice
site mutations and their consequences both at the mRNA
and protein levels. The search for additional intronic or
extragenic OA1genetic alterations, including deletions,
remains an important goal for future molecular investiga-
tions of X-linked recessive ocular albinism. However, all
forms of clinically diagnosed cases of apparently ocular
albinism are not necessarily X-linked recessive forms of
ocular albinism. This may explain, at least partially, the
apparently low level of molecular genetic alterations
detected by screening the OA1 gene in patients affected by
ocular albinism.
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